US ETFiShares· IBB· NASDAQ Biotechnology
iShares Biotechnology ETF
Issuer: BlackRock · Expense 0.45%
1Y Return
43.6%
YTD Return
0.8%
3Y CAGR
43.8%
5Y CAGR
43.8%
1Y Volatility
20.4%
1Y Sharpe
1.97
Max Drawdown
-9.7%
Close
$170.34
Profile
Asset class: equity
Region: US
Currency exposure: native
Monthly dividend: No
Leveraged: No
Pension-eligible: No
ISA-eligible: No
Themes
theme-biotechsector-healthcare
Related Inteliview Articles (2)
Pfizer Acquires Obesity Biotech Metsera, Enters GLP-1 War as Trump Medicare Coverage Launches
Pfizer acquires obesity biotech Metsera for billions, making a serious bid for the GLP-1 market. The…
May 5, 2026
Lilly and Novo Nordisk Locked In as Beneficiaries — Medicare to Cover GLP-1 Obesity Drugs for the First Time in July
Trump announced Medicare will cover Ozempic, Wegovy, and Zepbound at a $50 patient copay starting Ju…
May 2, 2026
Top 28 Holdings · KIS Open API
Official Korea Investment & Securities Open API. As of 2025-12-31.
N gurus = the number of Wall Street gurus (Buffett, Dalio, etc.) holding the same ticker per their latest 13F filings. Click through to see the full guru list on the asset detail page.
Distribution history — Phase 2
Will appear once SEIBro distribution data is loaded.
Gurus holding this ETF — Phase 4
Will appear once 13F holdings data is joined in.
Metrics as of 2026-05-05 · Last close 2026-05-05